Top

Published in:

01-11-2004 | Original Paper

Allogeneic stem cell transplantation for treatment of immunodeficiency

Authors: Wilhelm Friedrich, Susanna M. Müller

Published in: Seminars in Immunopathology | Issue 1-2/2004

Abstract

Primary immunodeficiencies constitute a group of highly complex congenital disorders commonly characterized by an extremely poor prognosis. Allogeneic hematopoietic stem cell transplantation has the potential to establish a permanently functioning immune system and represents a curative approach in many of these disorders. In this review several aspects of stem cell transplantation are presented, with an emphasis on the mechanism of immune reconstitution in severe combined immunodeficiency diseases. In this disorder transplant modalities vary, and also include transplantation without cytoreductive conditioning. Clinical results are summarized based on recent analysis performed in large patient cohorts, which have shown steady improvements and have led to a marked change in the prognosis of patients with primary immunodeficiencies.

Antoine C, Friedrich W, Cant A, et al (2003) Long term survival and hematopoietic stem-cell transplantation for immunodeficiencies. A survey of the European experience 1968–99. Lancet 361:553–560

Bach FH, Albertini RJ, Anderson JL, et al (1968) Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet II:1364–1366

Bertrand Y, Landais P, Friedrich W, et al (1999) Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the European society for immunodeficiency. J Pediatr 134:740–748

Blaese RM, Culver KW, MillerAD, et al (1995) T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270:475–480

Brochstein JA, Gillio AP, Ruggiero M, et al (1991) Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for corrections for Wiskott-Aldrich syndrome. J Pediatr 119:907–912

Buckley RH (2000) Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 343:1313–1324

Buckley RH, Schiff SE, Schiff RI, et al (1999) Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508–516

Candotti F, Notarangelo L, Visconti R, et al (2002) Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J Clin Invest 109:1261–1269

Cavazzana-Calvo M, Hacein-Bey S, Saint Basile G de, et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-Xl disease. Science 288:669–672

10.

Fischer A (2000) Severe combined immunodeficiencies (SCID). Clin Exp Immunol 122:143–149

11.

Fischer A (2001) Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 357:1863–1869

12.

Fischer A, Landais P, Friedrich W, et al (1990) European experience of bone marrow transplantation for severe combined immunodeficiency. Lancet 336:850–854

13.

Fischer A, Landais P, Friedrich W, et al (1994) Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for immunodeficiency. Blood 83:1149–1154

14.

Fischer A, Hacein-Bey S, Cavazzana-Calvo M (2002) Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol. 2:615–621

15.

Filipovich AH, Stone JV, Tomany SC, et al (2001) Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97:1598–1603

16.

Flake AW, Zanjani ED (1999) In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. Blood 94:2179–2191

17.

Friedrich W, Goldmann SF, Vetter U, et al (1984) Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet I:761–764

18.

Friedrich W, Goldmann SF, Ebell W, et al (1985) Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors. Eur J Pediatr 144:125–130

19.

Gatti RA, Meeuwissen HJ, Allen HD, et al (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet II:1366–1369

20.

Haddad E, Landais P, Friedrich W, et al (1998) Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 91:3646–3653

21.

Horwitz ME, Barrett AJ, Brown MR et al (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 344:881–888

22.

Kane L, Gennery AR, Crooks BN, et al (2001) Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal Ed 85:F110–113

23.

Kapoor N, Kirkpatrick D, Blaese RM, et al (1981) Reconstitution of normal megakaryocytopoiesis and immunological functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood 57:692–696

24.

Macchi P, Villa A, Giliani S, et al (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:65–68

25.

Moshous D, Callebaut I, Chasseval R de, et al (2001) Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 105:177–186

26.

Müller SM, Ege M, Pottharst A, et al (2001) Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood 98:1847–1851

27.

Noguchi M, Yi H, Rosenblatt HM, et al (1993) Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73:147–57

28.

O’Reilly RJ, Small TN, Friedrich W (2004) Hematopoietic cell transplant for immunodeficiency diseases. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Malden, pp 1430–1442

29.

Ozsahin H, LeDeist F, Benkerrou M, et al (1996) Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr 129:238–244

30.

Patel DD, Gooding ME, Parrott RE, et al (2000) Thymic function after haematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl Med J 342:1325–1332

31.

Persis A, Gaspar HB, Hassan A, et al (2000) Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96:1239–1245

32.

Pollack S, Kirckpatrick D, Kapoor N, et al (1982) Identification by HLA typing of intrauterine-derived maternal T cells in four patients with severe combined immunodeficiency. N Engl J Med 307:662–665

33.

Puck JM, Deschenes SM, Porter JC, et al (1993) The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 2:1099–1104

34.

Reisner Y, Kapoor N, Kirkpatrick D, et al (1983) Transplantation for severe combined immunodeficiency HLA-A, B, D, DR incompatible parental marrow fractionated by soybean agglutinin and sheep red blood cells. Blood 61:341–348

35.

Russell SM, Tayebi N, Nakajima H, et al (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid devlopment. Science 270:797–800

36.

Sarzotti M, Patel DD, Li X, et al (2003) T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. J Immunol 170:2711–2718

37.

Schwarz K, Gauss GH, Ludwig L, et al (1996) RAG mutations in human B cell-negative SCID. Science 274:97–99

38.

Thrasher AJ, Kinnon C (2000) The Wiskott-Aldrich syndrome. Clin Exp Immunol 120:2–9

39.

WHO Scientific Group Report (1999) Primary immunodeficiency diseases. Clin Exp Immunol 118:1–34

Title: Allogeneic stem cell transplantation for treatment of immunodeficiency
Authors: Wilhelm Friedrich
Susanna M. Müller
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1-2/2004
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-004-0158-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2004

Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts

Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases

Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products

Application of xenogeneic stem cells for induction of transplantation tolerance: present state and future directions

Autologous stem cell transplantation in hematological malignancies

Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials